Table 3.
Post-lenvatinib anti-cancer therapy in the 35 patients with unresectable hepatocellular carcinoma.
| Category | Liver Transplantation Group # (n = 10) | Control Group (n = 25) |
|---|---|---|
| Any post-lenvatinib anti-cancer treatment | 8 (80%) | 17 (68%) |
| TACE/TAE | 3 (30%) | 3 (12%) |
| Chemotherapy | 4 (40%) | 7 (28%) |
| Radiotherapy | 1 (10%) | 1 (4%) |
| Clinical trials | 0 | 2 (8%) |
| Palliative metastasectomy | 2 (20%) | 0 |
| Target Therapy | 4 (40%) | 7 (28%) |
| Carbozantinib | 2 (20%) | 0 |
| Regorafenib | 2 (20%) | 2 (8%) |
| Ramucirumab | 0 | 1 (4%) |
| Sorafenib | 0 | 1 (4%) |
| Thalidomide | 1 (10%) | 4 (16%) |
| Immune checkpoint inhibitors | 0 | 6 (24%) |
| Atezolizumab plus bevacizumab | 0 | 1 (4%) |
| Atezolizumab | 0 | 1 (4%) |
| Nivolumab | 0 | 3 (12%) |
| Pembrolizumab | 0 | 1 (4%) |
# Lenvatinib used for tumor recurrence after liver transplantation; TAE: transarterial embolization; TACE: transarterial chemoembolization.